eblasakimab   Click here for help

GtoPdb Ligand ID: 11770

Synonyms: ASLAN-004 | ASLAN004 | CSL 334 | CSL-334
Compound class: Antibody
Comment: The INN eblasakimab refers to a fully human, IgG4κ monoclonal antibody whose target is interleukin-13 receptor subunit α1 (IL13RA1). Eblasakimab represents a first-in-class agent against IL13Rα1. Blocking IL13Rα1 function is predicted to inhibit signalling by the pro-inflammatory cytokines IL-4 and IL-13.

The peptide sequences for the heavy and light chains in eblasakimab's INN record are claimed in patent WO2008060813A2 (Merck and CSL Behring) [2], and these map to the antibody identified as 10G5-6 therein. Interrogation of CSL Behring's pipeline webpage suggests that eblasakimab may be their anti-IL13Rα1 lead candidate ASLAN004, that is being developed for the treatment of allergic disorders such as atopic dermatitis and asthma. As of October 2021 ASLAN004 was licensed to ASLAN Pharmaceuticals. Further online investigation indicates that ASLAN004 was formerly known as CSL 334. Other than the associated patent, there is no clearly identifiable published information to verify the eblasakimab-ASLAN004 association. Our prediction is made in good faith, based on information in the public realm.
Click here for help
Classification Click here for help
Compound class Antibody
International Nonproprietary Names Click here for help
INN number INN
11881 eblasakimab
Synonyms Click here for help
ASLAN-004 | ASLAN004 | CSL 334 | CSL-334
Database Links Click here for help
GtoPdb PubChem SID 458923805
Search PubMed clinical trials eblasakimab
Search PubMed titles eblasakimab
Search PubMed titles/abstracts eblasakimab